|Bid||1.1550 x 0|
|Ask||1.2000 x 0|
|Day's Range||1.1700 - 1.2000|
|52 Week Range||0.9800 - 3.1600|
|Beta (3Y Monthly)||1.23|
|PE Ratio (TTM)||38.71|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||2.28|
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...
Every investor in Neuren Pharmaceuticals Limited (ASX:NEU) should be aware of the most powerful shareholder groups. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller com...
ACADIA Pharmaceuticals Inc. (ACAD), Neuren Pharmaceuticals Limited (NEU.AX), and Rettsyndrome.org (RSO) announced today that the positive results from a Phase 2 study conducted by Neuren, which evaluated the safety and efficacy of trofinetide in females with Rett syndrome (RTT), have been published in Neurology®, the medical journal of the American Academy of Neurology.
The nature of investing is that you win some, and you lose some. Unfortunately, shareholders of Neuren Pharmaceuticals Limited (ASX:NEU) have suffered share price declines over the last year. ToRead More...
Zero-debt allows substantial financial flexibility, especially for small-cap companies like Neuren Pharmaceuticals Limited (ASX:NEU), as the company does not have to adhere to strict debt covenants. However, it also faces Read More...
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is for those who would like to learn about Return On Read More...
I am writing today to help inform people who are new to the stock market and want to begin learning about how to value company based on its current earningsRead More...
ACADIA Pharmaceuticals Inc. (ACAD) and Neuren Pharmaceuticals Limited (NEU.AX) announced today that they have entered into an exclusive North American License Agreement for the development and commercialization of trofinetide for Rett syndrome and other indications. Neuren retains rights to develop and commercialize trofinetide for all indications outside of North America.